lifestyle.forkstofeet.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AgomAb Therapeutics N.V.
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
April 23, 2026
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
March 26, 2026
Agomab Announces Closing of Initial Public Offering
February 12, 2026
Agomab Announces Pricing of Initial Public Offering
February 11, 2026
Agomab Announces Launch of Initial Public Offering
February 2, 2026